Navi Medical Technologies has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Neonav® ECG Tip Location System.
This approval enables its use in hospitals across the United States, improving vascular access care for neonatal and paediatric patients.
Neonav® is the first system specifically designed for paediatric and neonatal use. It utilises real-time ECG signal analysis to ensure accurate placement of Central Venous Access Devices (CVADs), minimising the risks associated with misplacement and migration.
The system reduces reliance on chest X-rays for confirmation, helping to accelerate treatment and lower the likelihood of unintended complications.
The Neonav® system has the broadest indication for use among tip location systems currently available. It can be used for patients ranging from preterm newborns to adults, including the placement of very small 1Fr catheters in premature infants.
The system is also cleared for catheter placement in both upper and lower body veins.
An additional feature of the system is its ability to monitor catheter position after initial placement.
This helps to prevent serious health issues resulting from undetected catheter movement, a common challenge in neonatal and paediatric care.
